CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
56.71
+0.25 (0.44%)
At close: Dec 24, 2025, 1:00 PM EST
56.84
+0.13 (0.23%)
After-hours: Dec 24, 2025, 4:59 PM EST
CRISPR Therapeutics AG Employees
CRISPR Therapeutics AG had 393 employees as of December 31, 2024. The number of employees decreased by 14 or -3.44% compared to the previous year.
Employees
393
Change (1Y)
-14
Growth (1Y)
-3.44%
Revenue / Employee
$97,550
Profits / Employee
-$1,242,486
Market Cap
5.40B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 393 | -14 | -3.44% |
| Dec 31, 2023 | 407 | -51 | -11.14% |
| Dec 31, 2022 | 458 | -15 | -3.17% |
| Dec 31, 2021 | 473 | 63 | 15.37% |
| Dec 31, 2020 | 410 | 106 | 34.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRSP News
- 2 days ago - CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer - Benzinga
- 2 days ago - CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies - GlobeNewsWire
- 20 days ago - Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy - Seeking Alpha
- 5 weeks ago - CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy - Seeking Alpha
- 6 weeks ago - CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study - Reuters
- 6 weeks ago - CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering - GlobeNewsWire
- 2 months ago - CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform - GlobeNewsWire